Involvement of protein kinase C and Src tyrosine kinase in acute tolerance to ethanol inhibition of spinal NMDA-induced pressor responses in rats.
OBJECTIVE
The present study was carried out to examine the role of protein kinases in the development of acute tolerance to the effects of ethanol on spinal N-methyl-D-aspartate (NMDA) receptor-mediated pressor responses during prolonged ethanol exposure.


METHODS
Blood pressure responses induced by intrathecal injection of NMDA were recorded. The levels of several phosphorylated residues on NMDA receptor NR1 (GluN1) (NR1) and NMDA receptor NR2B (GluN2B) (NR2B) subunits were determined by immunohistochemistry and Western blot analysis.


RESULTS
Ethanol inhibited spinal NMDA-induced pressor responses at 10 min, but the inhibition was significantly reduced at 40 min following continuous infusion. This effect was dose-dependently blocked by chelerythrine [a protein kinase C (PKC) inhibitor, 1-1000 pmol] or PP2 (a Src family tyrosine kinase inhibitor, 1-100 pmol) administered intrathecally 10 min following ethanol infusion. A significant increase in the immunoreactivity of phosphoserine 896 of NR1 subunits (pNR1-Ser896) and phosphotyrosine 1336 of NR2B subunits (pNR2B-Tyr1336) was found in neurons of intermediolateral cell column during the development of tolerance. Levels of pNR1-Ser896 and pNR2B-Tyr1336 were also significantly increased in lateral horn regions of the spinal cord slices incubated with ethanol for 40 min in vitro. The increases in pNR1-Ser896 and pNR2B-Tyr1336 levels were inhibited by post-treatment with chelerythrine and PP2, respectively, both in the in vivo and in vitro studies.


CONCLUSIONS
The results suggest that activation of PKC and Src tyrosine kinase during prolonged ethanol exposure leading to increases in the levels of pNR1-Ser896 and pNR2B-Tyr1336 may contribute to acute tolerance to inhibition by ethanol of NMDA receptor function.
Hsieh
W-K
WK
Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.
Lin
H-H
HH
Lai
C-C
CC
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D004361:Drug Tolerance; D004789:Enzyme Activation; D000431:Ethanol / Q000494:pharmacology*; D007278:Injections, Spinal; D008297:Male; D016202:N-Methylaspartate / Q000008:administration & dosage / Q000494:pharmacology*; D010766:Phosphorylation; D010768:Phosphoserine / Q000378:metabolism; D019000:Phosphotyrosine / Q000378:metabolism; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology*; D021122:Protein Subunits / Q000037:antagonists & inhibitors / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism*; D019061:src-Family Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*
C409466:NR1 NMDA receptor; C121001:NR2B NMDA receptor; D021122:Protein Subunits; D016194:Receptors, N-Methyl-D-Aspartate; D010768:Phosphoserine; D019000:Phosphotyrosine; D000431:Ethanol; D016202:N-Methylaspartate; D019061:src-Family Kinases; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C
Nat Neurosci. 2001 Apr;4(4):382-90
11276228
J Neurochem. 2001 Feb;76(4):1073-9
11181827
Neuropharmacology. 2007 Sep;53(3):362-8
17644144
Neuroscientist. 2005 Feb;11(1):37-49
15632277
Methods Mol Med. 2004;99:109-21
15131333
Neuroscience. 1992;46(3):657-67
1372115
N Engl J Med. 1995 Jun 29;332(26):1733-7
7760888
Clin Exp Pharmacol Physiol. 2006 Sep;33(9):847-52
16922819
Alcohol Clin Exp Res. 1994 Feb;18(1):81-5
8198231
J Neurochem. 2001 Feb;76(3):737-44
11158244
Neuropharmacology. 2006 Sep;51(4):747-55
16806304
Br J Pharmacol. 2008 Mar;153 Suppl 2:S1-209
18347570
Br J Pharmacol. 2003 Nov;140(5):955-63
14517180
Pharmacol Ther. 2006 Jan;109(1-2):227-37
16102840
Biochem Pharmacol. 1998 Oct 1;56(7):789-98
9774140
Mol Neurobiol. 1998 Winter;17(1-3):1-15
9887443
Crit Rev Neurobiol. 2000;14(1):69-89
11253956
J Biol Chem. 2003 Mar 28;278(13):11020-5
12536146
Science. 1999 Jul 2;285(5424):93-6
10390370
J Physiol. 1995 Sep 1;487 ( Pt 2):453-63
8558476
Hypertension. 1987 Jul;10(1):67-73
3596770
Curr Opin Neurobiol. 2001 Jun;11(3):327-35
11399431
Alcohol Clin Exp Res. 1999 Sep;23(9):1552-60
10512323
Neuroscience. 2003;121(3):641-7
14568024
Nat Neurosci. 2002 Jul;5(7):641-8
12068305
J Neurosci. 2003 May 1;23(9):3623-32
12736333
Mol Pharmacol. 2001 May;59(5):960-4
11306676
Science. 1997 Oct 24;278(5338):698-701
9381182
Physiol Rev. 1994 Apr;74(2):323-64
8171117
Nat Neurosci. 1999 Apr;2(4):331-8
10204539
J Biomed Sci. 2004 Jul-Aug;11(4):482-92
15153783
Alcohol Clin Exp Res. 2002 Mar;26(3):340-6
11923586